Patients with Bloom syndrome, who have BLM germ-line mutation resulting in striking decreases in both mRNA and protein expression levels of BLM, are apt to develop diverse malignancies including breast cancer, prostate cancer, and lung cancer (52, 58). This evidence concerns the gene BLM and lung carcinoma.